On September 28, 2025, Insight Molecular Diagnostics Inc. granted stock options to executives, with Josh Riggs receiving options for 400,000 shares at $3.33 each, while other executives received 235,000 and 18,000 shares. An amendment to Dr. Ekkehard Schütz’s employment agreement extends his term beyond the original four years until terminated according to prior terms.